Acute Myeloid Leukemia: Clonal Hematopoiesis After Induction Chemotherapy

More than half of patients with acute myeloid leukemia (AML) achieve remission after intensive induction therapy with an anthracycline and cytarabine, but according to this study, relapse is common. By predicting the likelihood of relapse, this can aid physicians in better understanding the best options for patients after remission.

In this editorial, researchers examine successful intensive induction chemotherapy for AML and how to better predict the likelihood of relapse, which can help tailor the best choices for post-remission treatment.

Original source: http://www.nejm.org/doi/full/10.1056/NEJMe1802610